Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

Eli Lilly (LLY) has secured High Court approval to acquire clinical-stage biotech Centessa Pharmaceuticals (CNTA) for $38.00 per share in cash plus contingent value rights totaling up to $9.00 per share, representing a $7.8 billion transaction. This regulatory milestone removes a key execution risk and signals deal closure is imminent, clearing the final hurdle for consolidation in the specialty neurology market.

The acquisition structure reflects Lilly's confidence in Centessa's neurological pipeline, particularly its excessive daytime sleepiness franchise. The CVR component demonstrates risk-sharing between acquirer and seller regarding late-stage clinical outcomes, suggesting Lilly views these assets as high-potential but not yet de-risked. This is consistent with Lilly's strategic expansion into neurology and sleep disorders, therapeutic areas commanding premium valuations.

For LLY, the transaction adds intellectual property and development-stage compounds to its clinical portfolio at a ~$7.8 billion outlay—material but manageable given Lilly's $800B+ market cap and strong free cash flow generation. The deal does not materially threaten the parent's balance sheet or capital allocation strategy, though it confirms aggressive M&A appetite in specialty pharma.

Sector implication: This approval reinforces consolidation momentum in biotech and specialty pharmaceuticals. Larger integrated pharma firms are acquiring clinical-stage assets to secure future revenue streams and therapy areas with inelastic demand. Health Care investors may interpret this as positive signal of capital deployment and pipeline resilience within the pharmaceutical subsector.